查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030235

細胞健康篩檢市場－全球產業規模、佔有率、趨勢、機會、預測：按檢測類型、樣本、採集地點、地區和競爭格局分類，2021-2031年

Cellular Health Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Sample, By Site of Collection, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞健康篩檢市場預計將從 2025 年的 34.8 億美元成長到 2031 年的 60.4 億美元，複合年成長率為 9.63%。

該領域專注於透過分析生物標記來測量細胞活力和功能的診斷方法，旨在透過檢測代謝和氧化損傷等因素來識別疾病的早期徵兆。該領域的成長主要受全球向預防醫學和疾病早期檢測的轉變以及全球人口老化導致慢性病患病率不斷上升的推動，而個性化醫療和先進診斷技術的興起進一步促進了這一成長。市場發展的主要障礙是這些專業診斷的保險報銷有限，這限制了患者的就醫途徑並減緩了其普及。儘管來自行業組織的關於這個特定細分市場的準確且最新的數據仍然匱乏，但整個預防醫學領域正經歷著快速成長。世界衛生組織（WHO）在2023年指出，人口老化是推動醫療保健需求成長的重要因素，並預測2030年，全球六分之一的人口將超過60歲。預計這將進一步增加對早期診斷解決方案的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 34.8億美元
市場規模：2031年 60.4億美元
複合年成長率：2026-2031年 9.63%
成長最快的細分市場 多重測試面板
最大的市場 北美洲

市場促進因素

人口老化加劇是全球細胞健康篩檢市場的主要驅動力，因為老年人更容易受到與老齡化相關的細胞功能衰退和慢性疾病的影響。這種人口結構的變化自然增加了對預防性診斷的需求，因為細胞健康評估能夠提供有關生物老齡化和疾病風險的關鍵資訊。人們渴望在晚年保持高品質的生活，這促使他們使用這些檢測來追蹤細胞健康狀況，並在症狀出現之前及早發現異常。海德公園資本公司2025年夏季發布的報告也印證了這項需求，報告指出，95%的60歲以上成年人至少會患有一種慢性疾病。同時，檢測技術的顯著進步正在提高診斷的準確性、速度和可及性，從而推動市場成長。基因組學、蛋白質組學和先進成像技術的突破使得生物標記的精確測量成為可能，為全面、篩檢的篩檢方案設計鋪平了道路，這些方案深受醫療專業人員和患者的青睞。例如，根據Sagentia 2026年1月的報告，羅氏診斷公司於2025年11月同意向其Freenome癌症篩檢測試投資高達2億美元。這將補充羅氏當年在全球進行的310億次診斷測試。

市場挑戰

針對專業細胞健康評估的保險和公共醫療保險覆蓋範圍有限，是全球細胞健康篩檢市場成長的主要障礙。當這些先進的檢測無法獲得醫療系統的充分經濟支持時，患者往往被迫承擔高額的自付費用，從而經常延誤必要的診斷。這種經濟障礙直接限制了患者的就醫途徑，並阻礙了尖端篩檢技術的廣泛應用，儘管這些技術已被證實對疾病早期發現和預防性健康管理具有顯著益處。此外，報銷不足也威脅診斷檢查室的財務穩定性以及整個產業的擴張。如果沒有補償保障，檢查室就缺乏投資研發新型細胞健康技術的動力。 AdvaMed 在 2026 年 3 月的報告中重點強調了這一問題，該報告指出，診斷行業的成員每年需進行 1550 萬美元的報銷調整。此外，美國臨床實驗室協會（ACLA）在2025年10月發出警告，到2026年1月，約800種檢測項目的醫療保險報銷額將削減高達15%。這表明支付的不確定性會扼殺創新，限制檢測的可及性，並最終阻礙市場發展。

市場趨勢

直接面對消費者（DTC）的細胞檢測激增，標誌著市場格局的重大變革，使人們能夠在標準臨床環境之外主導自身健康。在便利性和對個人化健康數據日益成長的需求的推動下，消費者現在無需醫生轉診即可獲得細胞評估，從而更容易及早發現疾病風險並追蹤生活方式選擇對細胞健康的影響。這種自我檢測的廣泛應用正使DTC服務成為未來成長的主要驅動力。 2024年10月，診斷與實驗室醫學協會預測，到2030年，這個全球細分市場的規模將超過200億美元。同時，數位健康工具和穿戴式技術的引入正在改變市場，實現對生理生物標記的持續即時追蹤。這種組合正在將細胞層面的評估從偶爾的檢查室就診轉變為持續的監測過程，從而提供更全面的個人健康狀況整體情況。整合數位應用程式的穿戴式裝置可以監測壓力和睡眠等關鍵細胞指標，從而實現對潛在功能障礙的早期發現。這一趨勢得到了 NHS 供應鏈在 2024 年 9 月宣布的一項消息的支持，該消息稱將投資 9.24 億美元用於數位診斷框架，該框架計劃於 2025 年 8 月啟動。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞健康篩檢市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 測驗類型（單項測驗、多項測驗）
    • 檢體類型（血液、唾液、尿液、其他）
    • 檢體採集地點（家中、醫院/診所、檢測機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞健康篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞健康篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區細胞健康篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲細胞健康篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲細胞健康篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球細胞健康篩檢市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Telomere Diagnostics, Inc.
  • Quest Diagnostics Inc.
  • Laboratory Corporation of America Holdings
  • SpectraCell Laboratories Inc.
  • Cell Science Systems Corporation
  • Immundiagnostik AG
  • Repeat Diagnostics Inc.
  • OPKO Health Inc.
  • Genova Diagnostics Inc.
  • Titanovo Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 14418

The Global Cellular Health Screening Market is expected to expand from USD 3.48 billion in 2025 to USD 6.04 billion by 2031, reflecting a compound annual growth rate of 9.63%. This sector focuses on diagnostic methods that measure cellular vitality and function through the analysis of biomarkers, examining factors such as metabolism and oxidative damage to spot premature indications of illness. Growth in this field is largely fueled by a worldwide shift toward preventive care, early disease identification, and the increasing prevalence of chronic conditions among an aging global population, further supported by the rise of personalized medicine and advanced testing technologies. A major obstacle to market advancement is the restricted reimbursement for these specialized diagnostics, which limits patient access and slows widespread adoption. Although exact recent figures from industry groups for this specific niche are scarce, the overall preventive medicine sector is booming. The World Health Organization noted in 2023 that the aging demographic is heavily driving healthcare needs, predicting that by 2030, one in six individuals globally will be over 60, thereby amplifying the demand for early diagnostic solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.48 Billion
Market Size 2031USD 6.04 Billion
CAGR 2026-20319.63%
Fastest Growing SegmentMulti Test Panels
Largest MarketNorth America

Market Driver

The expanding elderly demographic acts as a major catalyst for the Global Cellular Health Screening Market, given that older adults are more vulnerable to age-induced cellular decline and chronic illnesses. This population shift naturally increases the need for preventive diagnostics, as cellular health evaluations provide vital information regarding biological aging and disease risks. A strong desire to preserve a high quality of life in later years promotes the use of these assessments to track cellular health and catch abnormalities before symptoms appear, a necessity highlighted by a Summer 2025 Hyde Park Capital report stating that 95% of adults over 60 have at least one chronic condition. At the same time, technological leaps in testing are driving market growth by improving the precision, speed, and availability of diagnostics. Breakthroughs in genomics, proteomics, and advanced imaging facilitate the exact measurement of biomarkers, paving the way for comprehensive, less invasive screening panels that appeal to both medical professionals and patients. For example, a January 2026 Sagentia report noted Roche Diagnostics agreed to a potential USD 200 million investment in Freenome's cancer screening assays in November 2025, complementing Roche's delivery of 31 billion diagnostic tests globally that same year.

Market Challenge

Restricted insurance and public health coverage for specialized cellular health assessments poses a formidable barrier to the growth of the Global Cellular Health Screening Market. When these advanced tests lack adequate financial backing from healthcare systems, patients are burdened with substantial out-of-pocket expenses, frequently discouraging them from pursuing necessary diagnostics. This financial hurdle directly limits patient access and impedes the widespread acceptance of cutting-edge screening methods, despite their proven advantages for early disease detection and preventive health management. Furthermore, the absence of sufficient reimbursement threatens the financial stability of diagnostic laboratories and the overall expansion of the sector. Without dependable compensation, laboratories have little motivation to fund the development of new cellular health technologies, an issue highlighted by AdvaMed's March 2026 report noting a USD 15.5 million annual reimbursement correction for diagnostic members. Additionally, the American Clinical Laboratory Association warned in October 2025 of impending Medicare cuts of up to 15 percent on nearly 800 tests by January 2026, illustrating how payment uncertainties can hinder innovation, restrict test availability, and ultimately stall market progress.

Market Trends

The surge in direct-to-consumer cellular testing marks a major evolution in the market, allowing people to take charge of their well-being outside of standard clinical environments. Fueled by a rising desire for easily accessible and tailored health data, consumers can now undergo cellular assessments without needing a doctor's referral, making it easier to catch early disease risks and track how lifestyle choices affect cellular health. This widespread acceptance of self-testing establishes direct-to-consumer services as a primary driver of future growth, with the Association for Diagnostics & Laboratory Medicine projecting in October 2024 that this global market segment could surpass USD 20 billion by 2030. Simultaneously, the incorporation of digital health tools and wearable technology is transforming the market by offering continuous, real-time tracking of physiological biomarkers. This combination shifts cellular assessments from occasional lab visits to a continuous monitoring process, providing a more complete picture of an individual's well-being. Wearables paired with digital apps monitor key cellular indicators like stress and sleep, enabling earlier detection of potential dysfunctions, a trend supported by NHS Supply Chain's September 2024 announcement of a USD 924 million investment in digital diagnostic frameworks launching in August 2025.

Key Market Players

  • Telomere Diagnostics, Inc.
  • Quest Diagnostics Inc.
  • Laboratory Corporation of America Holdings
  • SpectraCell Laboratories Inc.
  • Cell Science Systems Corporation
  • Immundiagnostik AG
  • Repeat Diagnostics Inc.
  • OPKO Health Inc.
  • Genova Diagnostics Inc.
  • Titanovo Inc.

Report Scope

In this report, the Global Cellular Health Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cellular Health Screening Market, By Test Type

  • Single Test Panels
  • Multi Test Panels

Cellular Health Screening Market, By Sample

  • Blood
  • Saliva
  • Urine
  • Others

Cellular Health Screening Market, By Site of Collection

  • Home
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Cellular Health Screening Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cellular Health Screening Market.

Available Customizations:

Global Cellular Health Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cellular Health Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Single Test Panels , Multi Test Panels)
    • 5.2.2. By Sample (Blood, Saliva, Urine, Others)
    • 5.2.3. By Site of Collection (Home, Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Cellular Health Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Sample
    • 6.2.3. By Site of Collection
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cellular Health Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Sample
        • 6.3.1.2.3. By Site of Collection
    • 6.3.2. Canada Cellular Health Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Sample
        • 6.3.2.2.3. By Site of Collection
    • 6.3.3. Mexico Cellular Health Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Sample
        • 6.3.3.2.3. By Site of Collection

7. Europe Cellular Health Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Sample
    • 7.2.3. By Site of Collection
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cellular Health Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Sample
        • 7.3.1.2.3. By Site of Collection
    • 7.3.2. France Cellular Health Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Sample
        • 7.3.2.2.3. By Site of Collection
    • 7.3.3. United Kingdom Cellular Health Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Sample
        • 7.3.3.2.3. By Site of Collection
    • 7.3.4. Italy Cellular Health Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Sample
        • 7.3.4.2.3. By Site of Collection
    • 7.3.5. Spain Cellular Health Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Sample
        • 7.3.5.2.3. By Site of Collection

8. Asia Pacific Cellular Health Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Sample
    • 8.2.3. By Site of Collection
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cellular Health Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Sample
        • 8.3.1.2.3. By Site of Collection
    • 8.3.2. India Cellular Health Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Sample
        • 8.3.2.2.3. By Site of Collection
    • 8.3.3. Japan Cellular Health Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Sample
        • 8.3.3.2.3. By Site of Collection
    • 8.3.4. South Korea Cellular Health Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Sample
        • 8.3.4.2.3. By Site of Collection
    • 8.3.5. Australia Cellular Health Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Sample
        • 8.3.5.2.3. By Site of Collection

9. Middle East & Africa Cellular Health Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Sample
    • 9.2.3. By Site of Collection
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cellular Health Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Sample
        • 9.3.1.2.3. By Site of Collection
    • 9.3.2. UAE Cellular Health Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Sample
        • 9.3.2.2.3. By Site of Collection
    • 9.3.3. South Africa Cellular Health Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Sample
        • 9.3.3.2.3. By Site of Collection

10. South America Cellular Health Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Sample
    • 10.2.3. By Site of Collection
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cellular Health Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Sample
        • 10.3.1.2.3. By Site of Collection
    • 10.3.2. Colombia Cellular Health Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Sample
        • 10.3.2.2.3. By Site of Collection
    • 10.3.3. Argentina Cellular Health Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Sample
        • 10.3.3.2.3. By Site of Collection

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cellular Health Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Telomere Diagnostics, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Quest Diagnostics Inc.
  • 15.3. Laboratory Corporation of America Holdings
  • 15.4. SpectraCell Laboratories Inc.
  • 15.5. Cell Science Systems Corporation
  • 15.6. Immundiagnostik AG
  • 15.7. Repeat Diagnostics Inc.
  • 15.8. OPKO Health Inc.
  • 15.9. Genova Diagnostics Inc.
  • 15.10. Titanovo Inc.

16. Strategic Recommendations

17. About Us & Disclaimer